학술논문
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Document Type
Article
Author
Long, Georgina V; Saw, Robyn P M; Lo, Serigne; Nieweg, Omgo E; Shannon, Kerwin F; Gonzalez, Maria; Guminski, Alexander; Lee, Jenny H; Lee, Hansol; Ferguson, Peter M; Rawson, Robert V; Wilmott, James S; Thompson, John F; Kefford, Richard F; Ch'ng, Sydney; Stretch, Jonathan R; Emmett, Louise; Kapoor, Rony; Rizos, Helen; Spillane, Andrew J; Scolyer, Richard A; Menzies, Alexander M
Source
In The Lancet Oncology July 2019 20(7):961-971
Subject
Language
ISSN
1470-2045